June 10th 2025
During a live event, Gary J. Schiller, MD, explored the outcomes of the phase 1/2 trial of tagraxofusp-erzs in patients with blastic plasmacytoid dendritic cell neoplasm.
FDA Extends PDUFA Date for Revumenib NDA for KMT2A-Rearranged Acute Leukemia
July 30th 2024The FDA has extended the PDUFA target action date for the new drug application of revumenib for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute leukemia to December 26, 2024.
Read More